Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Eur J Surg Oncol. 2022 Sep;48(9):2008-2013. doi: 10.1016/j.ejso.2022.05.004. Epub 2022 May 13.
Still now, the efficacy of anatomic resection (AR) for hepatocellular carcinoma (HCC) is controversial. The aim of this study is to examine it in our cohort and detect an optimal indicator for AR.
The present study included 656 patients with primary HCC within Milan criteria who underwent hepatectomy from 2000 to 2019. Our cohort was divided into AR (n = 378) and non-anatomic resection (NAR) (n = 278) groups, and 1:1 propensity score matching (PSM) was performed to minimize the effect of potential confounders. Recurrence-free survival (RFS), overall survival (OS), and a preoperative indicator for AR were examined.
210 patients from each group were well-matched, and preoperative confounding factors were balanced between the two groups. There was no significant difference in RFS and OS between the two groups before (RFS; HR = 0.89 P = 0.25, OS; HR = 1.08 P = 0.64) and after PSM (RFS; HR = 0.93 P = 0.60, OS; HR = 1.07 P = 0.75). Subgroup analysis showed that the survival improvement effect of AR was observed in cases with a fucosylated fraction of alfa-fetoprotein (AFP-L3) > 10% and poorly differentiation (P for interaction <0.05). Moreover, the logistic regression analysis showed that preoperative AFP-L3 > 10% was an independent predictor for poorly differentiation (OR = 2.58, P = 0.03).
The efficacy of AR for patients with primary HCC within Milan criteria was not shown. But it was suggested that AFP-L3 > 10% might be a preoperative indicator of AR for HCC within Milan criteria.
到目前为止,解剖性切除术(AR)治疗肝细胞癌(HCC)的疗效仍存在争议。本研究旨在检验我们队列中的疗效,并发现 AR 的最佳指标。
本研究纳入了 2000 年至 2019 年间接受肝切除术且符合米兰标准的 656 例原发性 HCC 患者。我们的队列分为 AR(n=378)和非解剖性切除术(NAR)(n=278)两组,采用 1:1 倾向评分匹配(PSM)以最小化潜在混杂因素的影响。分析无复发生存率(RFS)、总生存率(OS)和 AR 的术前指标。
每组 210 例患者匹配良好,两组之间术前混杂因素平衡。两组之间的 RFS 和 OS 在匹配前(RFS:HR=0.89,P=0.25;OS:HR=1.08,P=0.64)和匹配后(RFS:HR=0.93,P=0.60;OS:HR=1.07,P=0.75)均无显著差异。亚组分析显示,在 AFP-L3>10%和低分化的患者中,AR 的生存改善效果更为显著(P<0.05)。此外,logistic 回归分析显示,术前 AFP-L3>10%是低分化的独立预测因素(OR=2.58,P=0.03)。
对于符合米兰标准的原发性 HCC 患者,AR 的疗效并不明显。但提示 AFP-L3>10%可能是 AR 的术前指标。